NKGen Biotech, Inc.
DelistedCIK 1845459fmd_00S93RYFN5C5SBRFF67KT639FFManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Dec 31, 2020 to Mar 31, 2025, 17 periods
| Line item | FY2022 | FY2023 | FY2024 |
|---|---|---|---|
| Total revenues | 0 | 0 | – |
| Cost of revenue | 0 | 0 | – |
| Gross profit | 0 | 0 | – |
| Research and development | 17 | 16 | 11 |
| Operating income | (24) | (30) | (27) |
| Interest expense | 2 | 1 | 3 |
| Interest and investment income | 2 | – | – |
| Other non-operating income (expense) | 0 | (53) | (17) |
| Income before taxes | (27) | (83) | – |
| Income tax expense | 0 | 0 | 0 |
| Net income from continuing operations | (27) | (83) | – |
| Net income | (27) | (83) | (44) |